Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05634512 · ClinicalTrials.gov registry record
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
A clinical trial of Hematopoietic Cell Transplantation and Mucopolysaccharidosis Type I, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT05634512: Active study of Hematopoietic Cell Transplantation and Mucopolysaccharidosis Type I, sponsored by Masonic Cancer Center, University of Minnesota.
NCT05634512 is a study of Hematopoietic Cell Transplantation and Mucopolysaccharidosis Type I that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 13 participants, below the 236-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05634512, a study of Hematopoietic Cell Transplantation and Mucopolysaccharidosis Type I, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, observational multicenter study to collect blood from patients with mucopolysaccharidosis type IH undergoing laronidase therapy and a stem cell transplant. Sixteen patients will be enrolled over a 24 month period.
Primary Outcome
Measure indicators for body size and maturation contribute to variability in laronidase exposure in patients with MPS IH.
Conditions Studied
Interventions
- DRUG Laronidase therapy and a stem cell transplant
Study Locations (1)
Minnesota
- University of Minnesota Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2026-10-01 |
What the registry record for NCT05634512 still lists
NCT05634512 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 236-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Laronidase therapy and a stem cell transplant is the first listed.
NCT05634512 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05634512 about?
NCT05634512 is a clinical study titled "Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.". This is a prospective, observational multicenter study to collect blood from patients with mucopolysaccharidosis type IH undergoing laronidase therapy and a stem cell transplant. Sixteen patients will be enrolled over a 24 month period.
What is the current status of trial NCT05634512?
This trial is currently active not recruiting. The enrollment target is 13 participants. The study started on 2022-11-17. Estimated completion is 2026-10-01.
What conditions does trial NCT05634512 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplantation, Mucopolysaccharidosis Type I.
What interventions are being tested in trial NCT05634512?
The interventions under investigation include: Laronidase therapy and a stem cell transplant (DRUG).
Who is sponsoring clinical trial NCT05634512?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05634512 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
RECRUITING
-
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
RECRUITING
-
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
RECRUITING · Phase 1
-
FMT In High-Risk Acute GVHD After ALLO HCT
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI